Navigation Links
WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
Date:2/23/2010

SHANGHAI, China, Feb. 23 /PRNewswire-Asia/ -- WuXi PharmaTech ( WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

WuXi produces solid oral dosage forms-tablets and capsules-for use in clinical trials in its Shanghai c-GMP manufacturing facility. In its analytical testing facility, WuXi develops and validates methods of analyzing APIs and formulated drug products for properties such as potency, purity and solubility. The company also offers compound stability tests and tests necessary for the release of APIs and drug products for clinical trial use. WuXi also delivers services related to regulatory compliance with chemistry, manufacturing and controls, or CMC, requirements, including creation of a readiness testing package for an Investigational New Drug filing and development of a full CMC package.

"We are very pleased to have passed this EMEA audit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "The agency's inspection outcome confirms that these two facilities meet international GMP standards.

"We pride ourselves on the quality of our facilities, processes, and people," Dr. Li continued. "Research manufacturing and analytical testing are important functions in a continuum of integrated drug discovery and development services that WuXi provides to our global customers. Our mission is to help our global customers to improve the success of discovery and shorten the time of development of new medical products."

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Stephanie Liu
     Associate Director of Corporate Communications Department
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

     Web:   http://www.wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Back to top

RELATED LINKS
http://www.wuxiapptec.com

'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
2. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
3. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
4. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
5. Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals
6. Lilly Surpasses United Way 2009 Campaign Goal
7. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
8. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
9. Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day
10. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
11. Vision Inspection Systems Specialist Acquire Automation Expands Employee Base, Launches New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... N.Y. , Dec. 6, 2016  Licenders is bringing their ... This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is to ... treatment plans are designed to get children right back to class ... are 100% all natural and safe for the whole family," Licenders ...
(Date:12/6/2016)... Dec. 6, 2016  Alopexx Oncology, LLC announced data ... antibody fusion protein (immunocytokine) composed of interleukin-2 and a ... target on B cells as Rituxan and maintains the ... is also involved in tumor targeting, engagement of the ... The results of the study (abstract #95954) were presented ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... ... Mount Sinai Health System today announced the creation of the Medical Modeling ... order 3D models for their cases. Virtual reality, simulation, and 3D printing services ... resource will be the first of its kind catering to the unique patient-specific modeling ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... 06, 2016 , ... After 30 years with The Hearing ... announced her retirement from HASA at the end of 2016. ... individuals and families with hearing and speech services. She has overseen the establishment ...
(Date:12/6/2016)... ... ... It can be argued that people these days spend as much time searching ... their human friends and family. As pets have assumed a bigger role in ... pet products has also increased. , For this reason, America’s Pet Health ...
(Date:12/6/2016)... Atlanta, GA (PRWEB) , ... December 06, 2016 ... ... innovation and the impact of new federal healthcare regulations at the 7th annual ... Galleria Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare ...
Breaking Medicine News(10 mins):